Celebrate the success of the Hall family’s golf tournament raising $35,000 for Fragile X research, contributing over $327,000 to date for FRAXA Research Foundation.
Read more![Patrick’s PALS 28th Annual Basketball Tournament for FRAXA Breaks Record](https://www.fraxa.org/wp-content/uploads/2024/07/BBall-Action-3-720x300.jpg)
Patrick’s PALS 28th Annual Basketball Tournament for FRAXA Breaks Record
Recap of Patrick’s PALS 28: a successful 3-on-3 basketball fundraiser in Boston, raising $170,000+ for FRAXA Research Foundation.
Read more![QurAlis and UMass Chan Advance Fragile X Syndrome Treatment using ASOs (Antisense Oligonucleotides)](https://www.fraxa.org/wp-content/uploads/2024/06/richter-2024-720x300.jpg)
QurAlis and UMass Chan Advance Fragile X Syndrome Treatment using ASOs (Antisense Oligonucleotides)
Explore how QurAlis and UMass Chan are revolutionizing Fragile X syndrome treatment using advanced ASO technology, setting new standards in therapeutic development.
Read more![FRAXA Webinar – Fragile X Syndrome: The Anxious Brain](https://www.fraxa.org/wp-content/uploads/2024/06/Buchanan-Webinar-Anxious-Brain-thumbnail-720x300.png)
FRAXA Webinar – Fragile X Syndrome: The Anxious Brain
Please join Carrie Buchanan, MD, Fragile X Program Director at Greenwood Genetic Center, for a webinar on World Fragile X Day, July 22, 2024, at 11 AM ET. She will discuss how individuals with Fragile X experience high levels of anxiety, which can manifest in many different ways.
Read more![Fragile X Treatment Target Emerges from Neurolixis & FRAXA Collaboration](https://www.fraxa.org/wp-content/uploads/2024/06/serotonin-and-silhouette-of-a-man-head-720x300.jpg)
Fragile X Treatment Target Emerges from Neurolixis & FRAXA Collaboration
A new treatment target for Fragile X syndrome has emerged from multiple research labs and a pharmaceutical startup. Neurolixis, a FRAXA pharma partner, has announced a new Fragile X development program.
Read more![Exploring Advances Fragile X Research: Comprehensive Webinar Highlights – May 2024](https://www.fraxa.org/wp-content/uploads/2024/04/2024-05-Research-QA-part2-btn-720x300.png)
Exploring Advances Fragile X Research: Comprehensive Webinar Highlights – May 2024
Discover the latest in Fragile X research with insights from our May 2024 webinar. Learn about new FRAXA grants, key clinical trials, and scientific updates that are shaping the future of Fragile X syndrome treatments.
Read more![BK Channel Openers: A New Drug for Fragile X Is Ready for Clinical Trials](https://www.fraxa.org/wp-content/uploads/2024/05/Restoring-Synapses-BK-Channel-Opener-720x300.png)
BK Channel Openers: A New Drug for Fragile X Is Ready for Clinical Trials
Discover the promising new BK channel opener, SPG601, now entering clinical trials for Fragile X syndrome. Learn about its potential to restore synaptic function and address core symptoms.
Read more![Celebrate World Fragile X Day: July 22, 2024 – Global Landmarks Light Up](https://www.fraxa.org/wp-content/uploads/2024/05/Omaha2-e1716998470988-720x300.jpg)
Celebrate World Fragile X Day: July 22, 2024 – Global Landmarks Light Up
Celebrate World Fragile X Day on July 22, 2024 by lighting up landmarks. Join us in honoring Fragile X research and supporting affected families worldwide.
Read more![Recruiting: Tetra Therapeutics Phase 3 Clinical Trial of Zatolmilast in Fragile X Syndrome Tetra Therapeutics Phase 3 Clinical Trial of Zatolmilast in Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2024/02/Tetra-Therapeutics-Phase-3-Clinical-Trial-of-Zatolmilast-in-Fragile-X-Syndrome-720x300.png)
Recruiting: Tetra Therapeutics Phase 3 Clinical Trial of Zatolmilast in Fragile X Syndrome
Tetra Therapeutics has launched large scale clinical trials of their phosphodiesterase (PDE) inhibitor for males ages 9-45 with Fragile X syndrome. FRAXA Research Foundation’s basic and translational research pointed the way to phosphodiesterase inhibitors to treat Fragile X.
Read more![Recruiting: Harmony Biosciences Phase 3 Clinical Trial (RECONNECT) with At-Home Option](https://www.fraxa.org/wp-content/uploads/2022/11/RECONNECT-Virtual-Fragile-X-Clinical-Trial-Now-Enrolling-720x300.jpg)
Recruiting: Harmony Biosciences Phase 3 Clinical Trial (RECONNECT) with At-Home Option
Harmony Biosciences is now recruiting for the RECONNECT Phase 3 clinical trial of ZYN002, a potential treatment for Fragile X syndrome. The trial offers an at-home participation option, making it accessible for patients across the US, Australia, and the UK. Join us in this groundbreaking study and contribute to the future of Fragile X syndrome treatment.
Read more![Your Opinion Matters: Help Shape Gene Therapy Research for Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2024/05/gene-therapy-flyer-720x300.png)
Your Opinion Matters: Help Shape Gene Therapy Research for Fragile X Syndrome
Help shape the future of Fragile X syndrome treatment by sharing your thoughts on gene therapy. Your input is vital as we explore potential new treatments that target the genetic cause of FXS. Participate in the Patrick Wild Centre’s survey today and make your voice heard in this important research.
Read more![Renewed Hope: Navigating Towards a Cure for Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2024/04/Sutton_Todd_Mills_Rodriguez_015-e1712066000308-720x300.jpg)
Renewed Hope: Navigating Towards a Cure for Fragile X Syndrome
Discover how Dr. Peter Todd’s latest Fragile X Syndrome research offers hope for advanced treatments and a possible cure, marking a new era in FXS therapy.
Read more![Inside the FRAXA Drug Validation Initiative: Advancing Fragile X Treatments](https://www.fraxa.org/wp-content/uploads/2024/03/FRAXA-DVI-2024-6-720x300.jpg)
Inside the FRAXA Drug Validation Initiative: Advancing Fragile X Treatments
Explore how the FRAXA Drug Validation Initiative is revolutionizing Fragile X syndrome treatment, leading the charge towards innovative therapies and hope for affected families.
Read more![Pharmacologically Activating mGluR7 as a Novel Therapy for Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2023/04/Tsai-Kumar-720x300.jpg)
Pharmacologically Activating mGluR7 as a Novel Therapy for Fragile X Syndrome
Join Dr. Tsai and Dr. Kumar on a journey into novel treatment avenues for Fragile X syndrome. Learn how activating mGluR7 could be a game-changer, opening up uncharted therapeutic territory.
Read more![Two-Med Combo Normalized Behavior, Improved Memory in Fragile X Mice](https://www.fraxa.org/wp-content/uploads/2023/02/Sex-specific-Learning-Differences-Found-in-Fragile-X-Patients-Mouse-Model-700x300.png)
Two-Med Combo Normalized Behavior, Improved Memory in Fragile X Mice
Treating Fragile X syndrome will likely require a combination of drugs, as a single medication may not address all symptoms. At FRAXA-DVI, Dr. Patricia Cogram and her team recently tested a combination of two investigational new drugs in Fragile X mice, with support from Healx. Together ibudilast and gaboxadol rescued a wide array of symptoms in the mice.
Read more![Celebrating Teamwork: FRAXA’s 7th Year at Bruins 50/50 Event](https://www.fraxa.org/wp-content/uploads/2024/02/2024-01-Bruins-50-50-17-720x300.jpeg)
Celebrating Teamwork: FRAXA’s 7th Year at Bruins 50/50 Event
Celebrating FRAXA’s 7th year at Bruins 50/50 Event: teamwork and community unite for Fragile X research.
Read more![Shape Our Conversation: FRAXA Feedback Survey](https://www.fraxa.org/wp-content/uploads/2024/02/fraxa-Survey-2024-720x300.jpg)
Shape Our Conversation: FRAXA Feedback Survey
Join FRAXA’s mission in shaping a brighter future for Fragile X research. Share your thoughts in our brief survey by February 15 and help us tailor our communication to your interests. Your insights are invaluable in our 30th year of progress.
Read more![Callum Cup’s Big Win: Millburn Charity Soccer Raises $26K for Fragile X Research Callum Cup 2023 Group](https://www.fraxa.org/wp-content/uploads/2023/12/Group-720x300.png)
Callum Cup’s Big Win: Millburn Charity Soccer Raises $26K for Fragile X Research
Discover the inspiring story of the Callum Cup in Millburn, NJ – a charity soccer match that raised over $26,000 for Fragile X research. Join us in celebrating community spirit and a commitment to a vital cause.
Read more![Recruiting: Unveiling Probiotic Potential in Fragile X Syndrome Clinical Trial](https://www.fraxa.org/wp-content/uploads/2023/12/Fragile-X-team_Belgrade_Serbia-169-720x300.jpg)
Recruiting: Unveiling Probiotic Potential in Fragile X Syndrome Clinical Trial
First of its kind in Serbia, this clinical trial explores probiotic intervention as a potential treatment avenue for Fragile X syndrome.
Read more![$100,000 Matching Challenge From The Robert & Ardis James Foundation](https://www.fraxa.org/wp-content/uploads/2022/12/Ralph-James-quote-2022b-720x300.png)
$100,000 Matching Challenge From The Robert & Ardis James Foundation
We are thrilled to announce FRAXA Research Foundation’s most significant and unique matching challenge of the year, thanks to the Robert & Ardis James Foundation. This challenge will help us bring top new talent to Fragile X research.
Read more![Pharmacological Modulation of Nicotinic Signaling](https://www.fraxa.org/wp-content/uploads/2022/11/Yury-Garkun-Hirofumi-Morishita-scaled-e1668796214931-720x300.jpg)
Pharmacological Modulation of Nicotinic Signaling
Nicotine — familiar to any smoker — tickles nicotinic acetylcholine receptors in the brain. These receptors are key to important brain functions including learning and memory. This team will explore whether drugs that dampen these receptors can improve cognitive function in Fragile X.
Read more![Astrocyte Contribution to Sensory Hypersensitivity in Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2022/11/Dunaevsky-Bergdolt-720x300.jpg)
Astrocyte Contribution to Sensory Hypersensitivity in Fragile X Syndrome
Most Fragile X research has focused on one type of brain cells: neurons. But mounting evidence point to problems with astrocytes, star-shaped cells which are vitally important to normal brain function. This team is working to understand how astrocytes are involved in Fragile X and develop treatment approaches that targets astrocytes alone.
Read more![Your Support on Giving Tuesday 2023 is Transforming Research](https://www.fraxa.org/wp-content/uploads/2023/11/givingtuesday2023-thankyou-720x300.png)
Your Support on Giving Tuesday 2023 is Transforming Research
On Giving Tuesday 2023, the generosity of 191 donors raised $333,517 for FRAXA Research Foundation, advancing research and hope for a cure for Fragile X syndrome.
Read more![An Update from Harmony Biosciences on Giving Tuesday](https://www.fraxa.org/wp-content/uploads/2023/11/Jeffrey-M.-Dayno-720x300.jpg)
An Update from Harmony Biosciences on Giving Tuesday
Harmony Biosciences recently completed its acquisition of Zynerba Pharmaceuticals. I am excited for us to progress their work in pursuit of a treatment option for people living with Fragile X syndrome.
Read more![Reactivating the FMR1 Gene to Reverse Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2019/07/Jeannie-Lee-featured-720x300.png)
Reactivating the FMR1 Gene to Reverse Fragile X Syndrome
FRAXA Research Foundation is dedicated to funding breakthrough research, providing $240,000 to reactivate the FMR1 gene to combat Fragile X Syndrome, with the goal of restoring vital protein function and advancing towards a cure.
Read more